Status:
COMPLETED
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation
Lead Sponsor:
Pfizer
Conditions:
Smoking Cessation
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to measure the safety and efficacy of three doses of varenicline for smoking cessation.
Eligibility Criteria
Inclusion
- Subjects must have smoked on average of at least ten cigarettes per day during the past year
- Subjects must have no period of abstinence greater than three months in the past year
Exclusion
- Subjects with any history of cardiovascular disease
- Myocardial infarction
- Significant arrhythmias
- Poorly controlled hypertension
Key Trial Info
Start Date :
February 1 2000
Trial Type :
INTERVENTIONAL
End Date :
January 1 2002
Estimated Enrollment :
625 Patients enrolled
Trial Details
Trial ID
NCT00150241
Start Date
February 1 2000
End Date
January 1 2002
Last Update
October 19 2015
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Los Angeles, California, United States
2
Pfizer Investigational Site
Farmington, Connecticut, United States
3
Pfizer Investigational Site
Minneapolis, Minnesota, United States
4
Pfizer Investigational Site
Omaha, Nebraska, United States